Ontogeny of midazolam glucuronidation in preterm infants

Saskia N. De Wildt, Greg L. Kearns, Darryl J. Murry, Gideon Koren, John N. Van Den Anker

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG) is also decreased. The aim of our study was to investigate the urinary excretion of midazolam and its metabolites OHM and OHMG in preterm neonates following the intravenous (IV) or oral (PO) administration of a single M dose. Methods: Preterm infants (post-natal age 3-13 days, gestational age 26-34 4/7 weeks) scheduled to undergo a stressful procedure received a 30-min IV infusion (n=15) or a PO bolus dose (n=7) of 0.1 mg/kg midazolam. The percentage of midazolam dose excreted in the urine as M, OHM and OHMG up to 6 h post-dose was determined. Results: The median percentage of the midazolam dose excreted as M, OHM and OHMG in the urine during the 6-h interval after the IV infusion was 0.44% (range 0.02-1.39%), 0.04% (0.01-0.13%) and 1.57% (0.36-7.7%), respectively. After administration of the PO bolus dose, the median percentage of M, OHM and OHMG excreted in the urine was 0.11% (0.02-0.59%), 0.02% (0.00-0.10%) and 1.69% (0.58-7.31%), respectively. The proportion of the IV midazolam dose excreted as OHMG increased significantly with postconceptional age (r=0.73, p <0.05). Conclusion: The glucuronidation of OHM appears immature in preterm infants less than 2 weeks of age. The observed increase in urinary excretion of OHMG with postconceptional age likely reflects the combined maturation of glucuronidation and renal function.

Original languageEnglish (US)
Pages (from-to)165-170
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume66
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Midazolam
Premature Infants
Glucuronides
Urine
hydroxide ion
Intravenous Infusions
Cytochrome P-450 CYP3A

Keywords

  • CYP3A
  • Glucuronidation
  • Midazolam
  • Ontogeny
  • Urinary metabolic ratio

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ontogeny of midazolam glucuronidation in preterm infants. / De Wildt, Saskia N.; Kearns, Greg L.; Murry, Darryl J.; Koren, Gideon; Van Den Anker, John N.

In: European Journal of Clinical Pharmacology, Vol. 66, No. 2, 01.02.2010, p. 165-170.

Research output: Contribution to journalArticle

De Wildt, Saskia N. ; Kearns, Greg L. ; Murry, Darryl J. ; Koren, Gideon ; Van Den Anker, John N. / Ontogeny of midazolam glucuronidation in preterm infants. In: European Journal of Clinical Pharmacology. 2010 ; Vol. 66, No. 2. pp. 165-170.
@article{e93e99d4ca6240d195722d9b4a0748cb,
title = "Ontogeny of midazolam glucuronidation in preterm infants",
abstract = "Purpose: In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG) is also decreased. The aim of our study was to investigate the urinary excretion of midazolam and its metabolites OHM and OHMG in preterm neonates following the intravenous (IV) or oral (PO) administration of a single M dose. Methods: Preterm infants (post-natal age 3-13 days, gestational age 26-34 4/7 weeks) scheduled to undergo a stressful procedure received a 30-min IV infusion (n=15) or a PO bolus dose (n=7) of 0.1 mg/kg midazolam. The percentage of midazolam dose excreted in the urine as M, OHM and OHMG up to 6 h post-dose was determined. Results: The median percentage of the midazolam dose excreted as M, OHM and OHMG in the urine during the 6-h interval after the IV infusion was 0.44{\%} (range 0.02-1.39{\%}), 0.04{\%} (0.01-0.13{\%}) and 1.57{\%} (0.36-7.7{\%}), respectively. After administration of the PO bolus dose, the median percentage of M, OHM and OHMG excreted in the urine was 0.11{\%} (0.02-0.59{\%}), 0.02{\%} (0.00-0.10{\%}) and 1.69{\%} (0.58-7.31{\%}), respectively. The proportion of the IV midazolam dose excreted as OHMG increased significantly with postconceptional age (r=0.73, p <0.05). Conclusion: The glucuronidation of OHM appears immature in preterm infants less than 2 weeks of age. The observed increase in urinary excretion of OHMG with postconceptional age likely reflects the combined maturation of glucuronidation and renal function.",
keywords = "CYP3A, Glucuronidation, Midazolam, Ontogeny, Urinary metabolic ratio",
author = "{De Wildt}, {Saskia N.} and Kearns, {Greg L.} and Murry, {Darryl J.} and Gideon Koren and {Van Den Anker}, {John N.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1007/s00228-009-0741-5",
language = "English (US)",
volume = "66",
pages = "165--170",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Ontogeny of midazolam glucuronidation in preterm infants

AU - De Wildt, Saskia N.

AU - Kearns, Greg L.

AU - Murry, Darryl J.

AU - Koren, Gideon

AU - Van Den Anker, John N.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG) is also decreased. The aim of our study was to investigate the urinary excretion of midazolam and its metabolites OHM and OHMG in preterm neonates following the intravenous (IV) or oral (PO) administration of a single M dose. Methods: Preterm infants (post-natal age 3-13 days, gestational age 26-34 4/7 weeks) scheduled to undergo a stressful procedure received a 30-min IV infusion (n=15) or a PO bolus dose (n=7) of 0.1 mg/kg midazolam. The percentage of midazolam dose excreted in the urine as M, OHM and OHMG up to 6 h post-dose was determined. Results: The median percentage of the midazolam dose excreted as M, OHM and OHMG in the urine during the 6-h interval after the IV infusion was 0.44% (range 0.02-1.39%), 0.04% (0.01-0.13%) and 1.57% (0.36-7.7%), respectively. After administration of the PO bolus dose, the median percentage of M, OHM and OHMG excreted in the urine was 0.11% (0.02-0.59%), 0.02% (0.00-0.10%) and 1.69% (0.58-7.31%), respectively. The proportion of the IV midazolam dose excreted as OHMG increased significantly with postconceptional age (r=0.73, p <0.05). Conclusion: The glucuronidation of OHM appears immature in preterm infants less than 2 weeks of age. The observed increase in urinary excretion of OHMG with postconceptional age likely reflects the combined maturation of glucuronidation and renal function.

AB - Purpose: In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG) is also decreased. The aim of our study was to investigate the urinary excretion of midazolam and its metabolites OHM and OHMG in preterm neonates following the intravenous (IV) or oral (PO) administration of a single M dose. Methods: Preterm infants (post-natal age 3-13 days, gestational age 26-34 4/7 weeks) scheduled to undergo a stressful procedure received a 30-min IV infusion (n=15) or a PO bolus dose (n=7) of 0.1 mg/kg midazolam. The percentage of midazolam dose excreted in the urine as M, OHM and OHMG up to 6 h post-dose was determined. Results: The median percentage of the midazolam dose excreted as M, OHM and OHMG in the urine during the 6-h interval after the IV infusion was 0.44% (range 0.02-1.39%), 0.04% (0.01-0.13%) and 1.57% (0.36-7.7%), respectively. After administration of the PO bolus dose, the median percentage of M, OHM and OHMG excreted in the urine was 0.11% (0.02-0.59%), 0.02% (0.00-0.10%) and 1.69% (0.58-7.31%), respectively. The proportion of the IV midazolam dose excreted as OHMG increased significantly with postconceptional age (r=0.73, p <0.05). Conclusion: The glucuronidation of OHM appears immature in preterm infants less than 2 weeks of age. The observed increase in urinary excretion of OHMG with postconceptional age likely reflects the combined maturation of glucuronidation and renal function.

KW - CYP3A

KW - Glucuronidation

KW - Midazolam

KW - Ontogeny

KW - Urinary metabolic ratio

UR - http://www.scopus.com/inward/record.url?scp=76949088683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76949088683&partnerID=8YFLogxK

U2 - 10.1007/s00228-009-0741-5

DO - 10.1007/s00228-009-0741-5

M3 - Article

C2 - 19838691

AN - SCOPUS:76949088683

VL - 66

SP - 165

EP - 170

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2

ER -